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INTRODUCTION
Autism spectrum disorders are a heterogeneous clinical and 
genetic group of neurodevelopmental defects that are char-
acterized by impaired social communication functions and 
inappropriate repetitive behavior.1 This family of disorders is 
characterized by enormous phenotypic variability, from mild 
primary deficits in language pragmatics2 to major neurological 
phenotypes, such as that of Rett syndrome (OMIM 312750), 
where it co-occurs with epilepsy, motor impairment, and sleep 
disturbance.3 The disabilities associated with autism spectrum 
disorders are often so severe that affected individuals do not 
generally reach parenthood, thereby preventing comprehen-
sive familial genetic studies from being undertaken. However, 
genetic alterations are already recognized as major etiologi-
cal factors. In this regard, concordance with autism spectrum 
disorders is higher than with any other cognitive or behavioral 
disorder.4,5 In addition to the contribution of polymorphic vari-
ants that confer low or moderate risk of the appearance of these 
neurodevelopmental defects, a cause of autism spectrum disor-
ders can be the occurrence of de novo mutations affecting genes 
in a number of cellular pathways.6–8 A similar scenario can be 
proposed for the genetic contribution to the even more hetero-
geneous group of disorders classified as intellectual disabilities.9
Among the described genetic defects associated with intel-
lectual disabilities, our attention was caught by a single case 
report of an autistic patient carrying a de novo balanced para-
centric inversion 46, XY in (10)(q11.1;q21.3) in which the dis-
tal breakpoint disrupted what was at that time known as the 
TRIP8 gene,10 which has been characterized as a member of the 
jmJC domain-containing protein family involved in the methyl 
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Purpose: Autism spectrum disorders are associated with defects in 
social response and communication that often occur in the context 
of intellectual disability. Rett syndrome is one example in which 
epilepsy, motor impairment, and motor disturbance may co-occur. 
Mutations in histone demethylases are known to occur in several of 
these syndromes. Herein, we aimed to identify whether mutations in 
the candidate histone demethylase JMJD1C (jumonji domain con-
taining 1C) are implicated in these disorders.
Methods: We performed the mutational and functional analysis of 
JMJD1C in 215 cases of autism spectrum disorders, intellectual dis-
ability, and Rett syndrome without a known genetic defect.
Results: We found seven JMJD1C variants that were not present in 
any control sample (~ 6,000) and caused an amino acid change involv-
ing a different functional group. From these, two de novo JMJD1C 
germline mutations were identified in a case of Rett syndrome and 
in a patient with intellectual disability. The functional study of the 
JMJD1C mutant Rett syndrome patient demonstrated that the altered 
protein had abnormal subcellular localization, diminished activity to 
demethylate the DNA damage-response protein MDC1, and reduced 
binding to MECP2. We confirmed that JMJD1C protein is widely 
expressed in brain regions and that its depletion compromises den-
dritic activity.
Conclusions: Our findings indicate that mutations in JMJD1C con-
tribute to the development of Rett syndrome and intellectual disabil-
ity.
Genet Med advance online publication 16 July 2015
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group removal and renamed as JMJD1C (jumonji domain con-
taining 1C).11–13 Support for a role of JMJD1C in autism has 
been further fostered by large-scale exome sequencing studies 
in which three de novo variants have been identified,14,15 at least 
one of which is a loss-of-function mutation.15 However, two of 
the three described variants occurred in unaffected siblings. To 
investigate whether JMJD1C mutations occur in intellectual 
disability, Rett syndrome, and autism spectrum disorders, we 
performed a comprehensive screening to identify single nucle-
otide changes and indels in a large collection of 215 patients in 
whom a genetic defect had not previously been identified.
MATeRIALs AND MeTHODs
Patients
The samples used in this study consisted of 215 patients of 
either gender with autism, Rett syndrome, or intellectual dis-
ability from the Hospital Clínic, Sant Joan de Deu and Pompeu 
Fabra University, Barcelona, Catalonia, Spain. A cohort of 500 
healthy volunteers was obtained from the same geographic 
region (Catalonia, Spain). All were Caucasian individuals (such 
as in the case cohort) and were matched according to gender 
distribution (case cohort: female, 53% [114/215]; male, 47% 
[101/215]; control cohort: female, 58% [290/500]; male, 42% 
[210/500]). Ethical approval for the molecular genetic stud-
ies was obtained from each institutional review board. DNA 
was extracted from peripheral blood leukocytes using stan-
dard techniques. We measured DNA concentration with the 
Quant-iT Picogreen (Invitrogen, Life Technologies – Grand 
Island, NY) and then normalized all concentrations to 25–
50 ng/μl before proceeding with the Access Array amplification.
Fluidigm access array
Forty-eight pairs of primers were designed using the Access 
Array Amplicon Tagging Assay design service from Fluidigm to 
cover all 26 exons of the JMJD1C gene (NM_032776.1), includ-
ing exon-intron boundaries. These primers also contained the 
sequencing adaptors necessary for subsequent sequencing in 
the 454 GS Junior Sequencer.
Multiplex ligation-dependent probe amplification
Large rearrangements in the JMJD1C gene were studied using 
multiplex ligation-dependent probe amplification. We designed 
nine such probes specific to the JMJD1C gene and six control 
probes according to the instructions provided by MRC-Holland.
sanger sequencing
The variants were validated by Sanger sequencing using a BigDye 
Terminator v3.1 Cycle Sequencing Kit (Life Technologies, Grand 
Island, NY) in an Applied Biosystems 3730/DNA Analyzer 
(Applied Biosystems – Life Technologies –  Grand Island, NY). 
The raw data were analyzed with Codon Code Aligner Software 
(CodonCode Corporation – Centerville, MA).
exome sequencing
The patient and healthy parents were analyzed by whole exome 
sequencing with TruSeq Sample Preparation Kit (Illumina, 
San Diego, CA). Exomes were captured with TruSeq Exome 
Enrichment Kit (Illumina) and paired-end 100 × 2 sequenced 
with the HiScan SQ (Illumina). Format DNA and Protein 
Sequence Alignment Qual (FASTQ) files were analyzed as 
described in Supplementary Methods online. The raw data 
were analyzed in Centre Nacional d’Anàlisi Genòmica (CNAG), 
Barcelona, Catalonia, Spain.
Cell culture and vectors
JMJD1C coding sequence in the pCMV6-AC-GFP vector 
was purchased from Origene (Rockville, MD) (RG214878). 
The mutants were generated with Mutant QuikChange Site-
Directed Mutagenesis Kit (Agilent Technologies,  Santa Clara, 
CA). Wild-type (WT) WT and Pro163Leu and His2336Ala 
mutants were subcloned in the pCMV6-entry vector to intro-
duce  Myc-DDK-tag. shRNAs against the coding sequence of the 
mouse Jmjd1c gene were cloned in the pLVX-shRNA2 vector 
between the BamHI and EcoRI restriction sites (shRNA24 target: 
CAGAGACTGCTTGAGGAAT). Hek293 cells were cultivated 
in Dulbecco’s modified Eagles medium with 10% fetal bovine 
serum. To generate stable WT or mutant clones, Hek293 cells 
were transfected with Lipofectamine 2000 (Invitrogen), selected 
with G418 antibiotic, and individual clones were isolated 2 weeks 
later. For transient expression, 6 mg of vector were transfected 
in 35-mm six-well plates with jetPRIME transfection reagent 
(Polyplus, NY) following the manufacturer’s instructions. 
Primary cultures of hippocampal neurons were prepared from 
neonate mice (P0) of either sex. Cultures were infected at 3DIV 
with lentiviral vectors to express scramble or shRNAs against 
JMJD1C together with a GFP tracer (pLVX-shRNA2 system). 
Coverslips were fixed, and protein was extracted at 15DIV.
Immunoprecipitation
Seven hundred fifty micrograms of chromatin fraction were 
diluted 10-fold in immunoprecipitation (IP) buffer (5 mmol/l 
Tris–HCl pH 7.6, 15 mmol/l HEPES pH 8.0, 1 mmol/l Ethylene 
diamine tetraacetic acid, 1 mmol/l ethylene glycol tetraacetic 
acid, 0.1% sodium dodecyl sulfate (SDS), 1% Triton X-100) 
incubated with 2 μg of antibodies anti-Me-Lysine (Abcam 
ab23366, Cambridge, UK) overnight at 4 °C and for 2 hours 
with PureProteome Protein A/G Magnetic Beads. Beads were 
washed twice with IP buffer and twice in RBS NP-40 and eluted 
in laemli buffer in reduction conditions at 70 °C for 10 minutes.
MeCP2 immunoprecipitation
For the MeCP2 immunoprecipitation procedure, anti-JMJD1C 
and anti-MeCP2 antibodies were coupled to Dynabeads 
Protein G (Invitrogen). JMJD1C transfected HEK293F cells 
were transiently transfected with MeCP2-Flag tagged plas-
mid and the nuclear fraction was obtained by RIPA buffer (10 
mmol/l TRIS-Cl pH 8.0, 1 mmol/l EDTA (Ethylene diamine 
tetraacetic acid), 0.5 mmol/l EGTA (ethylene glycol tetraacetic 
acid), 1% Triton X-100, 0.1 % sodium deoxycholate, 0.1% SDS, 
and 140 mmol/l NaCl) supplemented with protease inhibi-
tors (complete; Roche, Rotkreuz, Switzerland) and hybridized 
with the antibodies at 4 °C for 2 hours. Then, 150 mM NaCl 
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phosphate-buffered saline (PBS) buffer was used for wash-
ing. Human IgG was used as negative control. Anti-Flag HRP 
(M2-SIGMA) antibody was used to visualize binding.
Western blot
Protein extract of Hek293 cells and primary neuronal culture 
were obtained in radioimmunoprecipitation assay (RIPA) buffer 
supplemented with a complete protease inhibitor cocktail tablet 
(Roche) and sonicated. Then, 50 μg of each protein sample were 
denatured in Laemli buffer 4% β-mercaptoethanol for 10 minutes 
at 95 °C, separated on a 7.5% or 15% SDS-polyacrylamide gel, 
and then transferred onto a polyvinylidene fluoride membrane 
(Immobilon-P; Millipore, Hessen, Germany) by liquid electrob-
lotting. The antibodies and dilutions used were as follows: rabbit 
anti-JMJD1C 1:2,000  (09-817; Millipore); mouse anti-nucleolin 
1:1,000 (SC-8031; Santa Cruz, Dallas, Texas); rabbit anti-H3 
1:10,000 (Abcam AB1791); mouse  anti-H3 1:4,000 (Abcam 
AB10799); and rabbit anti-MDC1 1:5,000 (Abcam AB11171). The 
blots were developed with Luminata Crescendo Western HRP 
substrate (MERCK MILLIPORE -  Hessen, Germany) or with the 
LiCor Odyssey System (LI-COR – Bad Homburg, Germany).
Immunofluorescence
Cells were fixed in 4% paraformaldehyde–phosphate-buffered 
serum (PFA-PBS), quenched in 100 mmol/l glycine-PBS, and 
permeabilized with 0.25% Triton X-100, 1% bovine serum albu-
min, and PBS. The cells were blocked with 0.2% gelatin and 
0.25% Triton X-100. Antibody dilutions were prepared in 0.25% 
Triton X-100, 1% bovine serum albumin, and PBS. The dilu-
tions used were: rabbit anti-JMJD1C 1:200; chicken anti-Map2 
1:5,000; and anti-β-tubulin 1:1,500 (Abcam AB21058). Nuclei 
were stained with 2 mg/ml Hoechst 33342. Coverslips were 
mounted in ProLong Gold antifade reagent (Molecular Probes 
– Life Technologies – Grand Island, NY). Confocal images were 
captured with a Leica SP5 confocal microscope (Leica, Buffalo 
Grove, IL). For fluorescence recovery after photobleaching anal-
ysis, the cells were maintained at 37 °C in an atmosphere of 5% 
CO2. We captured images every 70 seconds at 63×, at 128 × 128 
resolution, and at 1,400 Hz with bidirectional acquisition. We 
captured 25 control images at 3% laser transmission before 
bleaching and then bleached the region of interest (ROI) inside 
a nucleus 25 times at a nominal level of 100% laser transmission. 
For this experiment, 150 images were captured after bleaching. 
The row data were analyzed with FrapAnalyzer software (Igor 
Pro 6.1 Software – WaveMetrics – Lake Oswego, OR).
RNA extraction and real-time PCR
Total RNA was extracted from cell lysates using TRIzol Reagent 
(Invitrogen), purified using the RNeasy Kit (Qiagen, Valencia, 
CA), and 2 µg were retrotranscribed using the ThermoScriptTM 
RT-PCR System (Invitrogen). Real-time PCR reactions were 
performed in triplicate on an Applied Biosystems 7,900HT Fast 
Real-Time PCR system using 20 ng cDNA, 5 µl SYBR Green PCR 
Master Mix (Applied Biosystem), and 150 nmol/l specific prim-
ers (sequences are available on request) in a final volume of 10 µl.
ResULTs
JMJD1C mutational analyses in samples from autism 
spectrum disorders, intellectual disability, and Rett 
syndrome
We first collected blood samples in EDTA tubes for DNA extrac-
tion from 215 patients with autism spectrum disorders (n = 69; 
58 males and 11 females), intellectual disability (IQ < 70) (n = 85; 
43 males and 42 females), or Rett syndrome (n = 61; all females) 
without mutations in the disease-associated genes MECP2, 
CDKL5, and FOXG1.16 Approval for this was obtained from 
the corresponding institutional review boards. The presence of 
single-nucleotide changes and indels in the JMJD1C gene was 
analyzed by sequencing using a GSJUNIOR system with an 
amplicon library prepared with the Fluidigm Access Array, and 
the presence of larger genetic defects was assessed by multiplex 
ligation-dependent probe amplification. We detected no major 
genomic defects at the JMJD1C gene locus using the multiplex 
ligation-dependent probe amplification approach. Identified 
synonymous variants for JMJD1C are shown in Supplementary 
Table S1 online and seven previously informed JMJD1C nucleo-
tide variants are described in Supplementary Table S2 online. 
Most importantly, the sequencing strategy identified seven 
nucleotide changes in the exonic regions of JMJD1C that were not 
present in the NHLBI Exome Sequencing Project (ESP) Exome 
Variant Server (~6,000 control samples) (Supplementary Table 
S3 online). These seven nucleotide changes were also absent in 
the 1000 Genomes Project17 and the NCBI database of genetic 
variation.18 Furthermore, we sequenced 500 healthy volun-
teers for these seven missense variants and none of the studied 
samples showed the described changes (Supplementary Table 
S3 online and Supplementary Figure S1 online). Not finding 
prior documentation of a variant in a mutation database is not 
in itself evidence of pathogenicity, and most missense variants 
are rare due to factors such as rapid population growth and 
weak purifying selection.19 Interestingly, four of our seven (57%) 
missense mutations were clustered in the exon 10 of JMJD1C, 
where the only two previously reported JMJD1C missense 
mutations were also found14,15 (Figure 1a). In addition, the seven 
 single-nucleotide shifts caused an amino acid change involving 
a different functional group (Supplementary Table S3 online) 
that could alter important domains of the JMJD1C protein, 
such as the nuclear localization signal and the JmjC hydroxylase 
domain (Figure 1a). Unfortunately, for the understanding of the 
functional consequences of the JMJD1C mutations undergo-
ing study, the 3D structure of this protein is only available for 
the C-terminal end (amino acid positions from 2,157 to 2,497) 
corresponding to the JmJC domain.20 From the described muta-
tions only c. 6997A>G (T/A 2333) (Supplementary Table S3 
online) is included in the available structure, and the identified 
change affects a critical amino acid in one of the beta strands 
that confers the core beta barrel for histone substrate interac-
tion (Figure  1b). Conventional Sanger sequencing confirmed 
the GSJUNIOR sequencing results (Figure 1c). The seven point 
mutations described occurred in one case of Rett syndrome that 
was not associated with MECP2, CDKL5, and FOXG1 defects, 
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in three autistic patients, and in three patients with intellectual 
disability (Supplementary Table S3 online).
Our experimental, genetic, and clinical experiences with Rett 
syndrome enabled us to select the newly identified JMJD1C 
nucleotide change in this severe form of autism spectrum 
 disorder and further characterize its functional relevance. 
The c.  488C>T nucleotide change in exon 4 of the JMJD1C 
gene causes a proline-to-leucine shift in codon 163 of the 
Figure 1 Diagram of JMJD1C and mutations found. (a) Black asterisks indicate the position of mutations identified in the JMJD1C gene. The three previous 
mutations identified by Iossifov et al. and Neal et al. are indicated by green and orange asterisks, respectively. The most important motif and domains are: 
NLS_Bp, bipartite nuclear localization signal; C1_2, phorbol esther/diacylglycerol-binding domain; AR, androgen receptor-interacting zone; LxxL, motif involved 
in transcriptional regulation; JMJC, JmjC hydroxylase domain. (b) JMJD1C 3D structure for the C-terminal end corresponding to the JmjC domain derived 
from the Protein Data Bank (PDB) code 2YPD, X-Ray diffraction data for 2.1 Angstroms resolution. The T2333 amino acid is indicated by a black arrow. (c) 
Chromatograms of Sanger sequencing showing c.2830C>T, c.3559A>G, and c.3743A<G mutations.
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Figure 2 Characterization of the JMJD1C Pro163Leu mutation. (a) The Pro163Leu missense mutation is in a highly conserved region of JMJD1C. (b) 
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protein. The potential pathogenic involvement of the JMJD1C-
Pro163Leu change is also suggested because the wild-type pro-
line amino acid is highly conserved in all mammalian JMJD1Cs 
(Figure 2a), and because it is included in the balanced JMJD1C 
inversion that occurs in the aforementioned autistic patient.10
Our patient with the JMJD1C-Pro163Leu mutant is a 29-year-
old female who was born at term, weighed 3,800 g, and presented 
a 9/10 APGAR value. She showed stagnation in head growth 
and also in normal development at 14 months old and lost social 
interaction at 18 months old. The patient started to use single 
words at 20 months old and propositive sentences at 24 months 
old, but only babbled at 36 month old. The patient also presented 
gait dyspraxia, hand-washing stereotype, learning impairment, 
teeth grinding, air swallowing, kyphoscoliosis, and tonic epilepsy. 
She was diagnosed as having classical Rett syndrome from the 
clinical standpoint, but without mutations in the known MECP2, 
CDKL5, and FOXG1 Rett-associated genes. Sanger sequencing of 
the progenitors showed that neither of the parents was a carrier 
of the described JMJD1C nucleotide change (Figure 2b). Thus, 
the described mutation can be considered a de novo germline 
event. In this regard, from the other five identified JMJD1C mis-
sense changes that were not present in the NHLBI Exome Variant 
Figure 3 Differential subcellular localization, processing, and chromatin binding of JMJD1C-Pro163. (a) Upper panels show immunofluorescence with 
 anti-JMJD1C antibody in untransfected cells showing that the endogenous protein is localized predominantly in the cytoplasm; middle panels show clones 
expressing JMJD1C-WT- GFP, which is also localized in the cytoplasm; bottom panels show that clones expressing JMJD1C-P163-GFP have a nuclear signal. 
(b) Clones and control cells were fractionated to separate the cytoplasm (C), nuclear (N), and chromatin (Chr) fractions. Proteins were processed for western 
blot and blotted with compartment markers (upper panel) and with anti-JMJD1C (lower panel). JMJD1C-WT-GFP looks like endogenous protein (black arrow), 
but JMJD1C-P163-GFP shows several processed bands in nucleus and chromatin (green arrows). (c) Normalized fluorescence recovery after photobleaching 
assay (FRAP) in clones overexpressing JMJD1C-WT-GFP and JMJD1C-P163-GFP. The bleached area was situated above the nuclei. The mutant P163L recovers 
more slowly than WT and has a larger immobile fraction. (d) Chromatin fractions from Hek293 control cells and Hek293 clones expressing JMJD1C-WT-GFP 
and JMJD1C-Pro163Leu-GFP were immunoprecipitated with anti-Methyl-lysine antibodies and blotted with anti-MDC1. (e) JMJD1C transfected HEK293F cells 
were co-transfected with MeCP2-Flag and subjected to immunoprecipitation assay with anti-JMJD1C antibody, anti-MeCP2 antibody, and control rabbit IgG. 
The western blot using anti-Flag shows the interaction between JMJD1C and MeCP2 when JMJD1C is immunoprecipitated (top). JMJD1C-Pro163Leu mutant 
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Server, we identified by conventional Sanger sequencing an addi-
tional germline de novo mutation. The c. 3559A>G nucleotide 
change (T/A amino acid change) occurred in a patient with 
intellectual disability (case 4 in Supplementary Table S3 online) 
but it was not present in the parents (Supplementary Figure S2 
online). In a recently developed statistical framework to distin-
guish  disease-relevant mutations from background variation due 
to random expectation,21 JMJD1C (NM_032776) was reported 
as having a mutation probability of 9.0804e-05.21 Thus, out of 215 
samples we would expect to find 0.0195 mutated, so discovering 
2 de novo mutations out of 215 samples is higher than expected 
by chance (102.4-fold, binomial test, P = 1.9e-4). One possible 
way to explain the higher rate of observed JMJD1C mutations 
than that in the described study21 could be related to the fact that 
the previously analyzed 5,000 samples corresponded to autism 
spectrum disorders,21 whereas our work jointly profiled autism 
with Rett syndrome and intellectual disability. Most importantly, 
our two de novo mutations were only identified in these last two 
entities. Thus, the identified JMJD1C mutation rate could match 
the one reported21 because we did not find any de novo mutation 
in our 69 cases of autism spectrum disorders. Interestingly, when 
we applied the PMUT predictor for these two de novo JMJD1C 
mutations,22 a neural network trained with neutral and patho-
genic mutations extracted from the protein database SwissVar, 
we found that both of them were considered potentially patho-
genic. To discard any other pathogenic mutation in our Rett syn-
drome patient, the patient and the healthy parents were analyzed 
by whole exome sequencing as described in Methods. The only 
de novo mutation identified in the patient was the described c. 
488C>T nucleotide change in exon 4 of the JMJD1C. The com-
plete exome sequencing data of these three samples are available 
at the Sequence Read Archive (http://www.ncbi.nlm.nih.gov/sra) 
under the codes SRX667201 (patient), SRX667384 (mother), and 
SRX667386 (father).
Functional analyses of a Rett syndrome–associated 
JMJD1C-Pro163Leu mutation
To address the effects of the identified JMJD1C-Pro163Leu muta-
tion, we first studied the intracellular localization of the protein. 
Endogenous JMJD1C was mainly cytoplasmic in Hek293 cells 
(Figure 3a), a pattern that was also observed in the transfected 
JMJD1C-WT-GFP in stable clones (Figure 3a). However, clones 
expressing the mutant  JMJD1C-Pro163Ala-GFP forms show a 
strong nuclear mark (Figure 3a). To characterize the subcellu-
lar scenarios in which the mutant JMJD1C protein was located 
in more detail, we fractionated cytoplasmic, nuclear, and chro-
matin-bound proteins. We found that if endogenous and trans-
fected JMJD1C proteins were almost absent from the chromatin 
fraction, then the mutant JMJD1C-Pro163Ala-GFP was mark-
edly enriched in the chromatin (Figure 3b). The use of the fluo-
rescence recovery after photobleaching assay in nuclear areas 
confirmed that mutant JMJD1C-Pro163Ala-GFP had reduced 
recovery in comparison with the JMJD1C wild-type transfected 
protein (Figure 3c). Most importantly, we also found that the 
mutant JMJD1C-Pro163Ala protein was less efficient in demeth-
ylating a non-histone target of JMJD1C that has been recently 
identified, MDC1 (mediator of DNA-damage checkpoint 1), a 
regulator of the RAP80-BRCA1 branch of the DNA damage-
response pathway.13 Using immunoprecipitation with an anti-
body against methylated lysines followed by western blot with 
the MDC1 antibody, we observed that Hek293 cells overexpress-
ing the wild-type JMJD1C protein efficiently demethylated the 
MDC1 protein but that the mutant JMJD1C-Pro163Ala-GFP 
form showed diminished activity (Figure 3d). Thus, the studied 
JMJD1C mutation might also impair the repair of DNA dam-
age in the studied patient. However, JMJD1C could also exert 
additional functions. In this regard, using JMJD1C-transfected 
HEK293F cells that we have co-transfected with MECP2-Flag, 
we observed the interaction between JMJD1C and MECP2 by 
using the immunoprecipitation assay (Figure 3e). Importantly, 
the JMJD1C-Pro163Leu mutant protein cannot efficiently bind 
to MECP2 (Figure 3e). These findings could explain the role of 
JMJD1C in Rett syndrome, a disease mainly associated with de 
novo mutations in MECP2.3
Once we had shown the aberrant functions of the mutant 
JMJD1C protein in the above model, we wondered whether 
Figure 4 JMJD1C expression in human and mouse brain regions. 
CXF refers to frontal cortex; CP, Caudatus-Putamen; TH, thalamus; HIP, 
hippocampus; MB, midbrain; CB, cerebellum. (a) ISH analysis performed 
using a  2-month-old male mouse sample extracted from the Allen Brain Atlas 
Database (©2014 Allen Institute for Brain Science. Allen Mouse Brain Atlas 
[Internet]. Available at http://mouse.brain-map.org/). (b) Quantitative RT-PCR 
using three 18-month-old female samples. The y axis shows the fold-change 
in JMJD1C RNA expression, normalized with respect to thalamus expression, in 
relation to the RPL38 housekeeping gene. Error bars represent the SEM across 
different samples. (c) Quantitative RT-PCR using a sample from a 64-year-old 
male. The y axis shows the fold-change in JMJD1C RNA expression, normalized 
with respect to thalamus expression, in relation to the GUSB housekeeping 









JMJD1C RNA expression across human brain regions































CXF CP TH HIP MB CB PONS
CXF CP TH HIP MB CB PONS
GeNeTICs in MeDICINe  |  Volume 18  |  Number 4  |  April 2016
384
SÁEZ et al  |  JMJD1C mutations in Rett syndrome and intelectual disabilityOriginal research article
the disruption of the wild-type JMJD1C protein had any cel-
lular effect on a neuronal system. We first confirmed that 
JMJD1C was expressed in different brain regions by examining 
the Allen Brain Atlas Database (http://www.brain-map.org/) 
(Figure  4a).23 We also validated the widespread expression of 
JMJD1C throughout distinct regions of the mouse (Figure 4b) 
and human (Figure 4c) brain by quantitative RT-PCR. Then, we 
used the short hairpin RNA (shRNA) approach to analyze the 
impact of its loss in neurons. Lentiviral shRNA-mediated deple-
tion of JMJD1C was performed in primary neuronal cultures 
obtained from neonatal mouse hippocampus and JMJD1C pro-
tein downregulation was observed using western blot (Figure 5a) 
and immunofluorescence (Figure 5b). We studied the existence 
of changes in the dendrites in these JMJD1C-impaired cells. A 
significant reduction in the complexity of the dendritic process 
is known to be a common hallmark in Rett syndrome.24 In this 
regard, and using immunofluorescence for the dendrite marker 
Map2, we found that JMJD1C shRNA-depleted neurons showed 
diminished dendritic branching in comparison with shRNA-
scrambled control neurons (Figure  5c,d). Thus, a functional 
JMJD1C protein seems to be required for a correct dendritic 
pattern, and a defect in this gene could be associated with the 
dendritic impairment observed in autistic patients.
DIsCUssION
Our findings suggest that mutations in the candidate histone 
demethylase JMJD1C contribute to the development of intellec-
tual disability, including well-defined clinical entities such as Rett 
syndrome in those cases in which the usual mutations in MECP2, 
CDKL5, and FOXG1 are not present. Importantly, from a func-
tional standpoint, a JMJD1C mutant protein is unable to correctly 
demethylate the MDC1 DNA  repair-response protein but the 
wild-type JMJD1C protein plays a key role in dendritic activity.
It is interesting to note that many of the genes mutated in intel-
lectual disability have an epigenetic component,25,26 and JMJD1C 
can now be included in this growing list. Epigenetics can be 
Figure 5 JMJD1C expression in primary neuron culture and shRNA knockdown. 3DIV neuron primary cultures were infected with lentiviral vectors 
expressing shRNAs against JMJD1C or scramble shRNA. Neurons were maintained in 14DIV culture. (a) Western blot shows the bands of JMJD1C and the effect of 
a scramble shRNA and shRNA against JMJD1C on the exon 24. Only the shRNA24 reduces the expression. Anti-H3 histone antibodies were used for normalization. 
(b) Immunofluorescence against JMJD1C. Neurons infected with shRNA24 reduce the expression of JMJD1C; infected neurons were identified with GFP tracer 
under CMV promoter in viral vector and nuclei stained with Hoechst3342. (c) Map2 immunostaining showing dendritic branching in primary cell culture neurons 
transfected with JMJD1C shRNA24 or scramble shRNA (SCR; Control). JMJD1C downregulation via shRNA24 induced a marked reduction of the Map2 signal, 
demonstrating a decrease in the length of neuronal dendrites (red). (d) The dendritic length (Map2 staining) in primary cell culture neurons transfected with 
JMJD1C shRNA24 or scramble shRNA was calculated using IMAGEJ software. Five fields per condition were analyzed and the results are plotted as a bar graph. 
Bar errors represent SEM across different fields and P values are indicated. shRNA-mediated downregulation of JMJD1C significantly decreased dendritic length.
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broadly defined as the inheritance of gene activity that does 
not depend on the “naked” DNA sequence, and it includes the 
control of gene transcription by several chemical marks, such as 
DNA methylation and histone modifications. Examples include 
the methyl-CpG-binding protein MeCP2 in Rett syndrome, the 
chromatin remodeling protein CHD7 in CHARGE syndrome, 
and the histone methyltransferase NSD1 in Sotos syndrome.25,26 
The latter disorder is a representative case of how the importance 
of post-translational modifications of histone N-terminal tails in 
the genetic origin of neurodevelopmental disorders is becoming 
increasingly recognized. In this context, two mental retardation 
syndromes have been linked to mutations in the histone lysine 
demethylases KDM5C (previously known as JARID1C)27 and 
PHF8 (also known as JHDM1F).28 Thus, it is possible that muta-
tions in many other members of the large histone demethylase 
family are involved in the development of intellectual disability.29 
In this regard, although further research is required to under-
stand the molecular pathways that involve JMJD1C, our work 
highlights the increasing contribution of the genetic disruption 
of epigenetic genes to human neurodevelopmental disorders.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper 
at http://www.nature.com/gim
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